Stockscreener 앱 받기
1.05
3.67%
-0.04
시간 외 거래:
1.05
전일 마감가:
$1.09
열려 있는:
$1.07
하루 거래량:
3.60M
Relative Volume:
0.82
시가총액:
$206.51M
수익:
$116.33M
순이익/손실:
$-209.25M
주가수익비율:
-0.4953
EPS:
-2.12
순현금흐름:
$-135.49M
1주 성능:
+15.73%
1개월 성능:
-14.63%
6개월 성능:
-50.47%
1년 성능:
-49.52%
1일 변동 폭
$1.03
$1.10
1주일 범위
$0.8955
$1.11
52주 변동 폭
$0.8191
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
명칭
Esperion Therapeutics Inc
전화
734-887-3903
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.05 | 206.51M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-18 | 개시 | Goldman | Neutral |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-01 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2023-03-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-03-16 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 재개 | BofA Securities | Neutral |
| 2023-02-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 개시 | H.C. Wainwright | Buy |
| 2021-10-19 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-09 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 재개 | JP Morgan | Underweight |
| 2020-08-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 재개 | BofA/Merrill | Buy |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-16 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-03-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 재확인 | Needham | Strong Buy |
| 2018-12-13 | 개시 | Goldman | Sell |
| 2018-10-29 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-07-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-05-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
모두보기
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Esperion Reveals Next-Gen Cholesterol Treatment Strategy: FDA-Approved Non-Statin Leader Updates Growth Plans - Stock Titan
Esperion to Participate in The Citizens Life Sciences Conference - The Manila Times
Esperion unveils novel PSC treatment candidates By Investing.com - Investing.com Canada
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Esperion (ESPR) Advances ACLY Inhibitors for Rare Liver Disease Treatment | ESPR Stock News - GuruFocus
Esperion unveils novel PSC treatment candidates - Investing.com
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 - The Manila Times
New PSC Liver Disease Treatment Breakthrough: Promising Data Reveals Path to $1B Market Opportunity - Stock Titan
Esperion to Report First Quarter 2025 Financial Results on May 6 - The Manila Times
Esperion Q1 2025 Earnings Preview: What's Next for this FDA-Approved Cardiovascular Drug Maker? - Stock Titan
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Esperion stock hits 52-week low at $0.91 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $0.91 amid challenges - Investing.com
Esperion Therapeutics (ESPR) Faces Downward Earnings Estimate Re - GuruFocus
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 - The Manila Times
Esperion to Host R&D Day to Highlight Cardiometabolic - GlobeNewswire
Major Pipeline Expansion: Esperion to Reveal New Disease Target at R&D Day - Stock Titan
Esperion stock hits 52-week low at $1.17 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $1.17 amid challenges - Investing.com Australia
Esperion at Needham Conference: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Esperion announces CCO Eric Warren to step down - Investing.com Australia
Esperion announces CCO Eric Warren to step down By Investing.com - Investing.com Canada
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Diametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion Appoints Robert E. Hoffman as New Director - TipRanks
Esperion appoints Robert Hoffman to board of directors - Investing.com
Esperion appoints Robert Hoffman to board of directors By Investing.com - Investing.com UK
Esperion Appoints Robert E. Hoffman to Board of Directors - GlobeNewswire
Strategic Board Shake-up: Esperion Lands Former Kintara CEO Hoffman as Director - Stock Titan
Esperion stock hits 52-week low at $1.46 amid challenges By Investing.com - Investing.com South Africa
Esperion stock hits 52-week low at $1.46 amid challenges - Investing.com
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive: Esperion Reveals Next-Gen Drug Pipeline at Major Healthcare Conference - Stock Titan
BB Biotech AG Reduces Stake in Esperion Therapeutics Inc - GuruFocus
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia - Nasdaq
Esperion Therapeutics Says FDA Clears Phase 3 Bempedoic Acid Trial in Hypercholesterolemia - MarketScreener
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia - The Manila Times
Esperion Aligns with U.S. Food and Drug Administration to - GlobeNewswire
Esperion Therapeutics Inc (ESPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.06%
자본화:
|
볼륨(24시간):